PURPOSE: This article investigates the safety and efficacy of a simple @entity900 -based biochemotherapy regimen, containing single-agent @entity900 plus recombinant @entity1199 ( @entity5041 ) and recombinant interferon-alpha (rIFN-alpha), in the treatment of @entity320 . @entity1 AND METHODS: Between December 1990 and April 1997, 129 @entity1 were treated with @entity900 (100 mg/m2, day 0) plus continuous intravenous infusion @entity5041 (18 MIU/m2/day, days 3-6 and days 17-21) and subcutaneous rIFN-alpha (9 MIU three times per week) plus or minus @entity440 (160 mg/day) on three different protocols. @entity5 response, disease-free survival, and overall survival were evaluated for all evaluable @entity1 (N = 127). RESULTS: The overall response rate was 49%, and 10% of @entity1 achieved a complete response. Responses were observed at all sites of @entity3 . In one case, a @entity1 with a large cutaneous inguinal mass experienced a dramatic regression of that lesion within 1 month. The median disease-free survival was 5 months, and median overall survival was 11 months. @entity1 who responded had a significant survival advantage over nonresponders, and @entity1 who achieved a complete response had a significant survival advantage over @entity1 with a partial response. @entity137 were manageable and reversible upon discontinuation of therapy. CONCLUSION: The response rates achieved with this simple biochemotherapy regimen are comparable to those for other @entity900 -based biochemotherapy regimens, which use more complex multiagent chemotherapy regimens. We found no added clinical benefit from the addition of @entity440 to @entity900 .

Salp  tri  re Hospital experience with biochemotherapy in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicities'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumor'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity5041 :: ('116562(Tax:10116)', 'Gene') :: ['rIL-2'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity1199 :: ('3558', 'Gene') :: ['interleukin-2'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['metastatic melanoma']
